Akero Therapeutics, Inc. (AKRO) News

Akero Therapeutics, Inc. (AKRO): $12.75

-0.22 (-1.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter AKRO News Items

AKRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AKRO News Highlights

  • For AKRO, its 30 day story count is now at 9.
  • Over the past 17 days, the trend for AKRO's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • EFX and KPTI are the most mentioned tickers in articles about AKRO.

Latest AKRO News From Around the Web

Below are the latest news stories about Akero Therapeutics Inc that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year

GlobeNewswire | February 25, 2022

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Karyopharm Therapeutics (KPTI) H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $26.00. The company's shares closed last Wednesday at $9.13. According to TipRanks.

Brian Anderson on TipRanks | February 9, 2022

Akero finishes enrollment in phase 2b trial of efruxifermin in liver disease

Akero Therapeutics (AKRO -0.2%) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin (EFX) to treat non-alcoholic steatohepatitis (NASH). "Our confidence in EFX’s potential is based on Phase 2a data that showed substantial rates of fibrosis regression after only 16 weeks of treatment. We believe the larger Phase 2b HARMONY...

Seeking Alpha | February 8, 2022

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH).

GlobeNewswire | February 8, 2022

Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Yahoo | January 14, 2022

Akero Therapeutics (AKRO) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 12, 2022

Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Compa

Yahoo | January 4, 2022

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of Buy from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus recommendation of Buy from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued []

Dakota Financial News | December 3, 2021

Investment Analysts Weekly Ratings Changes for Akero Therapeutics (AKRO)

Akero Therapeutics (NASDAQ: AKRO) recently received a number of ratings updates from brokerages and research firms: 11/16/2021 Akero Therapeutics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $29.00 price target on the stock. According to Zacks, Akero Therapeutics Inc. is a clinical-stage []

Dakota Financial News | December 1, 2021

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T. A live webcast of the Company fireside chat will be available through the investor relatio

Yahoo | November 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5177 seconds.